首页> 美国卫生研究院文献>Frontiers in Neurology >Effects of Oligosaccharides From Morinda officinalis on Gut Microbiota and Metabolome of APP/PS1 Transgenic Mice
【2h】

Effects of Oligosaccharides From Morinda officinalis on Gut Microbiota and Metabolome of APP/PS1 Transgenic Mice

机译:巴戟天寡糖对APP / PS1转基因小鼠肠道菌群和代谢组的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer's disease (AD), a progressive neurodegenerative disorder, lacks preclinical diagnostic biomarkers and therapeutic drugs. Thus, earlier intervention in AD is a top priority. Studies have shown that the gut microbiota influences central nervous system disorders and that prebiotics can improve the cognition of hosts with AD, but these effects are not well understood. Preliminary research has shown that oligosaccharides from Morinda officinalis (OMO) are a useful prebiotic and cause substantial memory improvements in animal models of AD; however, the mechanism is still unclear. Therefore, this study was conducted to investigate whether OMO are clinically effective in alleviating AD by improving gut microbiota. OMO were administered to APP/PS1 transgenic mice, and potential clinical biomarkers of AD were identified with metabolomics and bioinformatics. Behavioral experiments demonstrated that OMO significantly ameliorated the memory of the AD animal model. Histological changes indicated that OMO ameliorated brain tissue swelling and neuronal apoptosis and downregulated the expression of the intracellular AD marker Aβ1−42. 16S rRNA sequencing analyses indicated that OMO maintained the diversity and stability of the microbial community. The data also indicated that OMO are an efficacious prebiotic in an animal model of AD, regulating the composition and metabolism of the gut microbiota. A serum metabolomics assay was performed using UHPLC-LTQ Orbitrap mass spectrometry to delineate the metabolic changes and potential early biomarkers in APP/PS1 transgenic mice. Multivariate statistical analysis showed that 14 metabolites were significantly upregulated, and 8 metabolites were downregulated in the model animals compared to the normal controls. Thus, key metabolites represent early indicators of the development of AD. Overall, we report a drug and signaling pathway with therapeutic potential, including proteins associated with cognitive deficits in normal mice or gene mutations that cause AD.
机译:阿尔茨海默氏病(AD)是一种进行性神经退行性疾病,缺乏临床前诊断生物标志物和治疗药物。因此,AD的早期干预是重中之重。研究表明,肠道菌群会影响中枢神经系统疾病,而益生元可以改善患有AD的宿主的认知能力,但这些作用尚未得到很好的理解。初步研究表明,巴戟天(OMO)的寡糖是一种有用的益生元,可在AD动物模型中显着改善记忆力。但是,机制尚不清楚。因此,本研究旨在研究O​​MO是否在通过改善肠道菌群来缓解AD方面临床有效。将OMO应用于APP / PS1转基因小鼠,并通过代谢组学和生物信息学鉴定了AD的潜在临床生物标志物。行为实验表明,OMO可以显着改善AD动物模型的记忆。组织学变化表明,OMO可改善脑组织肿胀和神经元凋亡,并下调细胞内AD标记物Aβ1-42的表达。 16S rRNA测序分析表明,OMO保持了微生物群落的多样性和稳定性。数据还表明,OMO是AD动物模型中有效的益生元,可调节肠道菌群的组成和代谢。使用UHPLC-LTQ Orbitrap质谱仪进行了血清代谢组学测定,以描绘APP / PS1转基因小鼠的代谢变化和潜在的早期生物标志物。多变量统计分析表明,与正常对照组相比,模型动物的14种代谢物显着上调,而8种代谢物下调。因此,关键代谢物代表了AD发展的早期指标。总体而言,我们报告了具有治疗潜力的药物和信号通路,包括与正常小鼠认知缺陷相关的蛋白质或引起AD的基因突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号